Studiets endepunkter omfattede samlet overlevelse, progressionsfri overlevelse (PFS), responsrate, varighed af respons, tid indtil forværring af lungecancerrelaterede symptomer (hoste, dyspnø og smerter), og sikkerhed.
Study endpoints included overall survival, progression-free survival (PFS), response rate, duration of response, time to deterioration of lung cancer-related symptoms (cough, dyspnoea and pain), and safety.